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Background: Natural Eggshell Membrane (NEM®) is a novel dietary supplement that contains 
naturally occurring glycosaminoglycans and proteins essential for maintaining healthy joint 
and connective tissues. Two single center, open-label human clinical studies were conducted 
to evaluate the efficacy and safety of NEM® as a treatment for pain and inflexibility associated 
with joint and connective tissue disorders.
Methods: Eleven (single-arm trial) and 28 (double-arm trial) patients received oral NEM® 
500 mg once daily for four weeks. The primary outcome measure was to evaluate the change 
in general pain associated with the treatment joints/areas (both studies). In the single-arm trial, 
range of motion (ROM) and related ROM-associated pain was also evaluated. The primary treat-
ment response endpoints were at seven and 30 days. Both clinical assessments were performed 
on the intent-to-treat (ITT) population within each study.
Results: Single-arm trial: Supplementation with NEM® produced a significant treatment 
response at seven days for flexibility (27.8% increase; P = 0.038) and at 30 days for general 
pain (72.5% reduction; P = 0.007), flexibility (43.7% increase; P = 0.006), and ROM-associated 
pain (75.9% reduction; P = 0.021). Double-arm trial: Supplementation with NEM® produced a 
significant treatment response for pain at seven days for both treatment arms (X: 18.4% reduction; 
P = 0.021. Y: 31.3% reduction; P = 0.014). There was no clinically meaningful difference 
between treatment arms at seven days, so the Y arm crossed over to the X formulation for the 
remainder of the study. The significant treatment response continued through 30 days for pain 
(30.2% reduction; P = 0.0001). There were no adverse events reported during either study and 
the treatment was reported to be well tolerated by study participants.
Conclusions: Natural Eggshell Membrane (NEM®) is a possible new effective and safe thera-
peutic option for the treatment of pain and inflexibility associated with joint and connective 
tissue (JCT) disorders. Supplementation with NEM®, 500 mg taken once daily, significantly 
reduced pain, both rapidly (seven days) and continuously (30 days). It also showed clinically 
meaningful results from a brief responder analysis, demonstrating that significant proportions 
of treated patients may be helped considerably from NEM® supplementation. The Clinical Trial 
Registration numbers for these trials are: NCT00750230 and NCT00750854.
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Background
It is estimated that 140 million adults in the United States (US) suffer from some form 
of joint or connective tissue (JCT) disorder (ie, arthritis, lupus, gout, fibromyalgia, neck Clinical Interventions in Aging 2009:4 236
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or back pain, etc.).1,2 As the population ages, this estimate is 
expected to grow rapidly. Traditional treatments for most of 
these disorders attempt to address only the symptoms (pain, 
inflammation, and discomfort) associated with the diseases. 
This usually involves the use of analgesics (ie, acetamino-
phen, oxycodone, propoxyphene) or nonsteroidal anti-inflam-
matory drugs (NSAIDs) (ie, ibuprofen, diclofenac, celecoxib) 
alone or in combination. Most of these treatments have shown 
limited effectiveness in randomized controlled clinical trials 
(RCTs)3–6 or are known to have significant and sometimes 
severe side effects. To avoid the cardiac risks,7,8 gastroin-
testinal issues,9,10 and dependency issues11,12 associated with 
traditional JCT treatments (particularly with long-term use), 
many patients have turned to complementary and alternative 
medicines (CAMs) such as dietary supplements.
Glucosamine, chondroitin, and methylsulfonylmethane 
(MSM) alone and in combination, are widely marketed as 
dietary supplements to treat joint pain due to osteoarthritis 
(OA). There have been two major human clinical trials that 
have investigated the role of glucosamine and chondroitin in 
the treatment of OA symptoms. The Glucosamine/chondroitin 
Arthritis Intervention Trial (GAIT), a 1583 patient, six-month 
trial sponsored by the National Institutes of Health (NIH), 
failed to show significant improvement in the Western Ontario 
and McMasters Universities (WOMAC) Osteoarthritis Index 
in the overall patient population for glucosamine, chondroi-
tin, or their combination.13 The Glucosamine Unum In Die 
(once-a-day) Efficacy (GUIDE) trial, a 318 patient, six-month 
European trial sponsored by industry, showed a small, 5%–6% 
improvement in total WOMAC Index score over placebo for 
glucosamine sulfate.14 Other vitamins, minerals, and botani-
cals such as kava, pine bark extract, capsicum, boswellia 
root extract, turmeric/curcumin, etc., are also marketed for 
various JCT pain maladies often with little or no clinical 
support. Because of their limited effectiveness, the search for 
additional CAMs to treat JCT disorders continues.
We present here the use of eggshell membrane as a pos-
sible new natural therapeutic for JCT disorders. Eggshell 
membrane is primarily composed of fibrous proteins such as 
collagen type I.15 However, eggshell membranes have also 
been shown to contain glycosaminoglycans, such as dermatan 
sulfate and chondroitin sulfate16 and sulfated glycoproteins 
including hexosamines, such as glucosamine.17 Other compo-
nents identified in eggshell membranes are hyaluronic acid,18 
sialic acid,19 desmosine and isodesmosine,20 ovotransferrin,21 
lysyl oxidase,22 lysozyme,23 and β-N-acetylglucosaminidase.24 
The discovery of eggshell membrane as a natural source of 
combined collagen, glucosamine, chondroitin, and hyaluronic 
acid has prompted the evaluation of this material as a potential 
treatment for joint and connective tissue pain. ESM Technolo-
gies, LLC (Carthage, MO, USA) has developed methods to 
efficiently and effectively separate eggshell membrane from 
eggshells to create an essentially shell-free eggshell membrane. 
The isolated membrane is then partially hydrolyzed using a 
proprietary process and dry-blended to produce 100% pure 
Natural Eggshell Membrane (NEM®) powder. Compositional 
analysis of NEM® conducted by ESM has identified a high con-
tent of protein and moderate quantities of glucosamine (up to 
1% by dry weight), chondroitin sulfate (up to 2%), hyaluronic 
acid (up to 2%), and collagen (Type I, up to 25%).
Two 1-month pilot clinical studies were conducted to 
evaluate the efficacy and safety of NEM® for the relief of 
the pain and discomfort associated with joint and connective 
tissue disorders. The results are presented herein.
Methods
study designs
Both studies were conducted according to a single center, 
open-label, controlled design and were conducted in the US 
in accordance with the US Food and Drug Administration’s 
principles of Good Clinical Practice (Title 21, Code of 
Federal Regulations, Parts 50 and 56 and ICH E6) and the 
Declaration of Helsinki. The study protocols were approved 
by an independent institutional review board (The Copernicus 
Group) and patients provided their written informed consent 
to participate. Subjects were required to suspend all current 
pain relief medications in order to participate in the study. For 
the double-arm trial, eligible subjects were then randomized 
either to NEM® formulation X or NEM® formulation Y treat-
ment groups in the order in which they were enrolled in the 
study using a block randomization table. NEM® formulations 
X and Y differed in the degree (Y ∼2.5×  X) to which they 
were partially hydrolyzed prior to final ingredient blending. 
The clinical investigators were not blinded to treatment 
(open label) (both studies) or randomization (double-arm 
trial), however the subjects were blinded to randomization 
in the double-arm trial. Treatment consisted once daily orally 
of either NEM® (Membrell, LLC, Carthage, MO, USA) 
(single-arm trial) or two different formulations of NEM® 
(double-arm trial) provided in 500 mg vegetarian capsules 
that were stored in closed containers at ambient temperature. 
Clinic visits were scheduled for subjects at seven and 30 days 
following the onset of treatment. Treatment compliance was 
checked at clinic visits by patient interview and by count-
ing the number of unused doses of the study medications. 
Although discouraged, acetaminophen was allowed for pain Clinical Interventions in Aging 2009:4 237
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relief rescue, if necessary. Subjects recorded the time and 
amount of acetaminophen taken in patient diaries.
Patients
All subjects aged 18 years or older and seeking relief of mild to 
moderate pain due to joint or connective tissue disorders were 
considered for enrollment in the studies. In order to be eligible, 
subjects must have had persistent pain (lasting at least three 
months) associated with a JCT disorder, with a minimum base-
line pain level of 2 on a 0 to 10 analog Likert scale. Subjects 
were required to suspend all current pain relief medications. 
Subjects that were currently taking analgesic medications were 
eligible to participate in the studies following a 14-day washout 
period for NSAIDs, a seven-day washout for narcotics, and a 
90-day washout for injected steroids. Subjects currently taking 
glucosamine, chondroitin sulfate or MSM were only eligible 
after a three-month washout period. Patients were excluded if 
they were currently receiving remission-inducing drugs such 
as methotrexate or immunosuppressive medications or had 
received them within the past three months. Other exclusion-
ary criteria were: body weight 113.5 kilograms (250 lbs.) or 
greater, a known allergy to eggs or egg products, or pregnant or 
breastfeeding women. Subjects previously enrolled in a study 
to evaluate pain relief within the past six months or currently 
involved in any other research study involving an investiga-
tional product (drug, device, or biologic) or a new application 
of an approved product, within 30 days of screening were also 
excluded from participating in the trials.
Treatment response
single-arm trial
The primary outcome measure of this study was to evaluate 
the mean effectiveness of NEM® in relieving general pain 
associated with moderate JCT disorders. Additional primary 
outcome measures were to evaluate flexibility, as well as the 
pain associated with the range of motion (ROM) evaluation. 
The primary treatment response endpoints were the 7 and 
30 day clinic assessments utilizing a 0 to 10 analog Likert-
scale, with 0 equating to no pain and 10 equating to most 
severe pain. Patients were asked to record a number equating 
to the perceived pain from the treatment joint/area. Endpoints 
were then compared to pretreatment assessments.
Double-arm trial
The primary outcome measure of this study was to evaluate the 
mean effectiveness of NEM® in relieving general pain asso-
ciated with moderate JCT disorders. Subjects were allowed 
to evaluate multiple treatment joints/areas. The primary 
treatment response endpoints were the seven and 30 day 
clinic assessments utilizing a 0 to 10 analog Likert scale, 
with 0 equating to no pain and 10 equating to most severe 
pain. Patients were asked to record a number equating to 
the perceived pain from the treatment joints/areas. Endpoints 
were then compared to pretreatment assessments.
Adverse events
Secondary objectives of both studies were to evaluate toler-
ability and any adverse reactions associated with supple-
mentation with NEM®. The subjects’ self-assessment diaries 
were reviewed and any discomfort or other adverse events 
were recorded and reported in accordance with applicable 
FDA regulations. Adverse events and serious adverse events 
were assessed by the clinical investigator at each study visit 
and followed until resolution, as necessary. Serious adverse 
events (those that result in either death, a life-threatening 
experience, inpatient hospitalization, a persistent or signifi-
cant disability or incapacity; or require, based on reasonable 
medical judgment, a medical or surgical intervention to pre-
vent an outcome described previously) were required to be 
reported to the clinical monitor immediately.
statistical analysis
As these were pilot studies with nonspecified treatment 
joints/areas, no enrollment sample size estimates were per-
formed for statistical power determination. Comparisons of 
the two treatment groups (double-arm trial) were made with 
a two-sided independent group t-test at baseline to validate 
randomization. Statistical significance was accepted at an 
α value of 0.05. Post-baseline statistical analyses were 
done as pairwise comparisons utilizing a two-sided t-test. 
Statistical significance was accepted at an α value of 0.05. 
Analysis of the primary outcome measure (the change from 
baseline in general pain levels (both studies), as well as 
flexibility and ROM-associated pain (single-arm trial)) was 
conducted in the intent-to-treat (ITT) population (ie, includ-
ing all patients with at least one efficacy assessment). The last 
observation carried forward (LOCF) approach was used for 
patients who made at least one follow-up visit but who did 
not complete the study (lost to follow-up). A per-protocol 
completer analysis was also performed. SYSTAT software 
(version 12) was used for all statistical analyses.25
Results
single-arm trial
Patient recruitment began in October 2003 at a single clinical 
site in Missouri (USA) and the final follow-up was conducted 
in December 2003. A total of 11 subjects were enrolled with Clinical Interventions in Aging 2009:4 238
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various joint and connective tissue conditions. Of these subjects, 
five (45%) were female and six (55%) were male. The treatment 
joints/areas consisted of knees (3), hips (1), elbows (1), neck 
(1), shoulders (1), and lower back (4). All 11 subjects com-
pleted baseline evaluations and were therefore used as the ITT 
population. Ten (91%) of the 11 ITT subjects completed the 
one-month study per the protocol. Of the 11 subjects in the ITT 
population, one subject did not begin treatment and, therefore, 
was not available for further analysis. Compliance with the 
study treatment regimen was good in the treatment group. In 
those subjects that completed the study, the rate of compliance 
was 98% (as judged by capsule count at clinic visits).
A clinical comparison of valid subjects was carried out to 
obtain a mean baseline pain value for the study population of 
3.6 ± 1.8 (mean ± standard deviation), a mean flexion ROM 
of 64.2° ± 36.5°, and a mean ROM-associated pain value of 
2.9 ± 2.6. Statistical analysis of the primary outcome mea-
sures revealed that supplementation with NEM® produced 
a significant treatment response at seven days for flexibility 
(27.8% increase; P = 0.038) and at 30 days for general pain 
(72.5% reduction; P = 0.007), flexibility (43.7% increase; 
P = 0.006), and ROM-associated pain (75.9% reduction; 
P = 0.021) (see Table 1). Overall, the use of rescue pain 
medication was extremely low throughout the study, occur-
ring once in every 20–22 days.
Double-arm trial
Patient recruitment began in November 2003 at a single clinical 
site in Missouri (USA) and the final follow-up was conducted in 
February 2004. A total of 28 subjects were enrolled with vari-
ous joint and connective tissue conditions, some with multiple 
treatment joints/areas. Of these subjects, six (21%) were male 
and 22 (79%) were female. The treatment joints/areas consisted 
of knees (7), hips (8), neck (1), shoulders (9), hands (2), legs 
(1), feet (1), lower back (4), and nonspecific (3). All 28 subjects 
completed baseline evaluations and were therefore used as the 
ITT population. Fourteen subjects (50%) were randomized 
to the NEM® X formulation treatment group and 14 subjects 
(50%) were randomized to the NEM® Y formulation treatment 
group. Twenty (71%) of the 28 ITT subjects completed the 
one-month study per the protocol. Of the 28 subjects in the 
ITT population, two subjects assigned to the X arm did not 
begin treatment and, therefore, were not available for further 
analysis. One patient in the X arm and 1 patient in the Y arm 
officially withdrew from the study due to lack of efficacy. The 
overall drop-out rate of 29% (from enrollment) was higher 
than expected, although 77% of the subjects that began treat-
ment (n = 26) completed the study. Compliance with the study 
treatment regimen was good in both treatment groups. In those 
subjects that completed the study, the rate of compliance 
was 96% (as judged by capsule count at clinic visits).
Patient data was initially evaluated to ensure randomization 
between groups (P = 0.097). A clinical comparison of valid 
subjects was carried out to obtain a mean baseline pain value 
(mean ± standard deviation) for each arm (X and Y) of the study 
(X: 6.8 ± 1.9; Y: 5.6 ± 1.9). Statistical analysis of the primary 
outcome measures revealed that supplementation with NEM® 
produced a significant rapid treatment response for pain at seven 
days for both treatment arms (X: 18.4% reduction; P = 0.021. 
Y: 31.3% reduction; P = 0.014). The 12.9% difference between 
treatment arms was not as large as was expected from the dif-
ference in the formulations. It was decided that this difference 
was not clinically meaningful. Therefore, at seven days the 
Y arm crossed over to the X formulation for the remainder of 
the study. The significant treatment response continued through 
30 days for pain (30.2% reduction; P = 0.0001) (See Table 2). 
Overall, the use of rescue pain medication was extremely low 
throughout the study, occurring once in every 14–16 days. 
There were no significant differences between the treatment 
arms for rescue medication use.
Both study populations were too small to stratify the 
patients according to covariates, such as gender or treatment 
joint/area, to obtain statistically relevant data. There were no 
adverse events or serious adverse events reported during either 
of the studies. Of particular note is that there were no allergy-
associated adverse events during the studies, although those 
with known egg allergies were excluded from participating 
during screening. In general, the treatment was reported to be 
extremely well tolerated by study participants.
Discussion
Joint and connective tissue disorders are extremely common in 
the United States and result in significant costs, both financial 
and quality of life, for those that suffer from the debilitating 
diseases. These two pilot clinical trials were designed to evalu-
ate the efficacy and safety of NEM® as a treatment option for 
JCT disorders. Results from both pilot studies suggest that 
NEM® is both effective and safe for treating pain associated 
with JCT disorders and considerably improves flexibility in 
the affected joints/areas. NEM® has the added benefit of avoid-
ing the concerning side effects associated with long-term use 
of other JCT treatments, such as narcotics or NSAIDs.
Patients experienced relatively rapid (seven days) 
responses for pain (double-arm trial) with a mean response 
of approximately 25% (X: 18.4%; Y: 31.3%) and flexibility 
(single-arm trial) with a mean response of approximately 28%. Clinical Interventions in Aging 2009:4 239
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The single-arm trial failed to reach statistical significance at 
seven days for pain. This is likely a result of the relatively high 
standard deviation at baseline (1.8) compared to mean pain at 
baseline (3.6). Each arm of the double-arm trial had a similar 
number of patients (X: 12; Y: 14) as in the single-arm trial (10) 
and yet had statistically significant results for pain at seven 
days. However the baseline means (X: 6.8; Y: 5.6) and stan-
dard deviations (both 1.9) were relatively better proportioned 
than the single-arm trial. The use of the pairwise t-test helps to 
mitigate the effects of a high standard deviation in determining 
statistical significance.
By the end of the follow-up period (30 days) the mean 
response for pain had improved to 30% (double-arm trial) and 
73% (single-arm trial). At the same time, flexibility improved 
to a mean response of approximately 44% and the ROM-associ-
ated pain had a mean response of approximately 76% (single-
arm trial). A brief responder analysis of the data provides a 
number of clinically relevant highlights. In both the single-arm 
trial and the double-arm trial, a significant proportion of the 
study populations (64% and 35%, respectively) experienced a 
greater than 50% reduction in pain by 30 days. Of particular 
note is that nearly half (45%) of the patients in the single-arm 
trial reported that they were pain-free (reported a score of 0) 
by 30 days of supplementation. All patients in the single-arm 
trial experienced at least some improvement in flexibility or 
ROM-associated pain, with more than half (55%) of the subjects 
experiencing a greater than 50% improvement in flexibility and 
more than one-third (36%) of the subjects reporting that they 
were pain-free during ROM evaluation. The safety profile for 
NEM® is also of significance as there are no known side effects, 
excluding the obvious egg allergy concern. This is of obvious 
importance in a condition that requires long-term treatment such 
as JCT disorders. Significant and sometimes serious side effects 
associated with other treatments can force patients to have to 
make the difficult decision between living with the disease 
symptoms or living with the side effect symptoms.
Both trials suffered from a limited initial enrollment (11 and 
28 subjects), however both trials had relatively low drop-out 
rates (9% and 29%). As both trials were also open label, there 
is the obvious issue of the placebo effect. The inclusion of a 
placebo control would have provided greater clinical meaning, 
however it would have required a significantly larger study 
population. The inclusion of such a broad range of JCT disorders 
with vastly differing pathologies could have readily led to 
ambiguous treatment effects. Additionally, a broad spectrum of 
disease severity was included in both trials which could have 
also led to ambiguous results. Despite these potential pitfalls, 
the results from these open-label trials suggest that NEM® may 
be an effective therapeutic for a broad range of JCT disorders. 
A larger study with some modifications is clearly warranted.
Table 1 single-arm trial mean values by category at baseline, 7 and 30 days post-treatment
  Days post-treatment Mean ± SD Percent improvement P-value
general Pain Baseline (n = 11) 3.6 ± 1.8 – –
7 (n = 11) 2.7 ± 1.7 25.8% 0.515
30 (n = 11) 1.0 ± 1.2 72.5% *0.007
Flexion (ROM) Baseline (n = 11) 64.2° ± 36.5° – –
7 (n = 11) 82.0° ± 41.4° 27.8% *0.038
30 (n = 11) 92.2° ± 38.4° 43.7% *0.006
ROM Pain Baseline (n = 11) 2.9 ± 2.6 – –
7 (n = 11) 1.7 ± 2.1 43.3% 0.112
  30 (n = 11) 0.7 ± 1.3 75.9% *0.021
Notes: P-values were determined by pairwise, two-sided, t-test comparison, and represent treatment versus baseline. *P  0.05.
Abbreviations: ROM, range of motion; sD, standard deviation.
Table 2 Double-arm trial mean pain values at baseline, 7 and 30 days post-treatment
Days post-treatment X Mean ± SD Y Mean ± SD Percent improvement P-value
Baseline (n = 12, 14) 6.8 ± 1.9 5.6 ± 1.9 – –
7 (n = 12, 14) 5.5 ± 2.0 3.9 ± 2.5 18.4%, 31.3% *0.021, *0.014
30 (n = 26) 4.3 ± 2.3 – 30.2% *0.0001
Notes: P-values were determined by pairwise, two-sided, t-test comparison, and represent treatment versus baseline. *P  0.05.
Abbreviation: sD, standard deviation.Clinical Interventions in Aging 2009:4
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With so many people suffering from joint and connective 
tissue disorders, and that number expected to grow immensely 
as the overall US population ages, it is important for patients 
to have treatment options that are both effective and safe. The 
reporting of the results from these two open-label pilot studies 
demonstrates that NEM® may be a viable treatment option for 
the management of JCT disorders. In these clinical studies, 
NEM®, 500 mg taken once daily, significantly reduced pain, 
both rapidly (seven days) and continuously (30 days). It also 
showed clinically meaningful results from a brief responder 
analysis, demonstrating that a significant proportion of treated 
patients may benefit from NEM® supplementation.
Disclosure
KJR is currently employed by the sponsor of both studies. 
DPD has served as a paid consultant for the sponsor of the 
studies. MDL and MAR have no competing interests. KJR 
carried out the statistical analysis of the data and drafted the 
manuscript. DPD participated in the design of both studies, 
assisted in the statistical analysis of the data, and assisted in 
drafting the manuscript. MDL was the clinical investigator 
for the Double-Arm Trial and assisted in drafting the manu-
script. MAR was the clinical investigator for the Single-Arm 
Trial and assisted in drafting the manuscript. All authors 
read and approved the final manuscript. The authors would 
like to acknowledge Dr Barry W. Ritz, Drexel University, 
Department of Bioscience and Biotechnology, USA, for 
his assistance with the preparation of this manuscript. Both 
studies were sponsored by ESM Technologies, LLC.
References
  1.  Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the 
Prevalence of Arthritis and Other Rheumatic Conditions in the United 
States. Part I. Arthritis Rheum. 2008;58(1):15–25.
  2.  Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the preva-
lence of arthritis and other rheumatic conditions in the United States. 
Part II. Arthritis Rheum. 2008;58(1):26–35.
  3.  Altman RD. Ibuprofen, acetaminophen and placebo in osteoarthritis 
of the knee: a six-day double-blind study [abstract]. Arthritis Rheum. 
1999;42:S403.
  4.  Case JP, Baliunas AJ, Block JA. Lack of efficacy of acetaminophen in 
treating symptomatic knee osteoarthritis: A randomized, double-blind, 
placebo-controlled comparison trial with diclofenac sodium. Arch Intern 
Med. 2003;163:169–178.
  5.  Geba GP, Weaver AL, Polis AB, Dixon ME, Schnitzer TJ. Efficacy of 
rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: 
a randomized trial. JAMA. 2002;287(1):64–71.
  6.  Towheed TE, Maxwell L, Judd MG, Catton M, Hochberg MC, 
Wells G. Acetaminophen for osteoarthritis. Cochrane Database Syst 
Rev. 2006;1:CD004257.
  7.  Singh G, Wu O, Langhorne P, Madhok R. Risk of acute myocardial 
infarction with nonselective non-steroidal anti-inflammatory drugs: 
a meta-analysis. Arthritis Res Ther. 2006;8(5):153–162.
  8.  Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk 
associated with celecoxib in a clinical trial for colorectal adenoma 
prevention. N Engl J Med. 2005;352:1071–1080.
  9.  Deeks JD, Smith LA, Bradley MD. Efficacy, tolerability, and upper 
gastrointestinal safety of celecoxib for treatment of osteoarthritis and 
rheumatoid arthritis: systematic review of randomised controlled trials. 
Brit Med J. 2002;325:619–627.
10.  Laine L. Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest 
Endosc Clin N Am. 1996;6(3):489–504.
11.  Porter J, Jick H. Addiction rate in patients treated with narcotics. N Engl 
J Med. 1980;320:123–126.
12.  Weaver M, Schnoll S. Addiction issues in prescribing opioids for 
chronic nonmalignant pain. J Addict Med. 2007;1(1):2–10.
13.  Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, 
and the two in combination for painful knee osteoarthritis. N Engl J 
Med. 2006;354(8):795–808.
14.  Herrero-Beaumont G, Ivorra JAR, Trabado MC, et al. Glucosamine 
sulfate in the treatment of knee osteoarthritis symptoms. Arthritis 
Rheum. 2007;56(2):555–567.
15.  Wong M, Hendrix MJC, von der Mark K, Little C, Stern R. Collagen 
in the egg shell membranes of the hen. Dev Biol. 1984;104(1):28–36.
16.  Baker JR, Balch DA. A study of the organic material of hen’s-egg shell. 
Biochem J. 1962;82:352–361.
17.  Picard J, Paul-Gardais A, Vedel M. Sulfated glycoproteins from egg 
shell membranes and hen oviduct. Isolation and characterization of 
sulfated glycopeptides. Biochim Biophys Acta. 1973;320:427–441.
18.  Long FD, Adams RG, DeVore DP. Preparation of hyaluronic acid from 
eggshell membrane. US Patent #6946551, September 20, 2005.
19.  Nakano T, Ikawa NI, Ozimek L. Chemical composition of chicken 
eggshell and shell membranes. Poult Sci. 2003;82:510–514.
20.  Starcher BC, King GS. The presence of desmosine and isodesmo-
sine in eggshell membrane protein. Connect Tissue Res. 1980;8(1): 
53–55.
21.  Gautron J, Hincke MT, Panheleux M, et al. Ovotransferrin is a matrix 
protein of the hen eggshell membranes and basal calcified layer. Conn 
Tissue Res. 2001;42:255–267.
22.  Akagawa M, Wako Y, Suyama K. Lysyl oxidase coupled with cata-
lase in egg shell membrane. Biochim Biophys Acta. 1999;1434(1): 
151–160.
23.  Hincke MT, Gautron J, Panheleux M, et al. Identification and localiza-
tion of lysozyme as a component of eggshell membranes and eggshell 
matrix. Matrix Biol. 2000;19:443–453.
24.  Ahlborn GJ, Clare DA, Sheldon BW, Kelly RW. Identification of 
eggshell membrane proteins and purification of ovotransferrin and 
β-NAGase from hen egg white. Protein J. 2006;25(1)71–81.
25.  Systat Software, Inc., San Jose, CA. 2007. Accessed May 10, 2007. 
Available from: http://www.systat.com/.